TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
出版年份 2016 全文链接
标题
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
作者
关键词
-
出版物
LEUKEMIA
Volume 30, Issue 6, Pages 1263-1272
出版商
Springer Nature
发表日期
2016-02-22
DOI
10.1038/leu.2016.34
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Versatile functions for IL-6 in metabolism and cancer
- (2015) Jan Mauer et al. TRENDS IN IMMUNOLOGY
- Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
- (2014) S. Branford et al. BLOOD
- TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
- (2014) D. T. Yeung et al. BLOOD
- Cancer-related inflammation and treatment effectiveness
- (2014) Connie I Diakos et al. LANCET ONCOLOGY
- The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice
- (2014) T R Rosean et al. LEUKEMIA
- A ‘telomere-associated secretory phenotype’ cooperates with BCR-ABL to drive malignant proliferation of leukemic cells
- (2014) M Braig et al. LEUKEMIA
- EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation
- (2014) Hanane Lanaya et al. NATURE CELL BIOLOGY
- Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
- (2013) T. P. Hughes et al. BLOOD
- Autocrine TNF- production supports CML stem and progenitor cell survival and enhances their proliferation
- (2013) P. Gallipoli et al. BLOOD
- Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
- (2013) S. Branford et al. BLOOD
- Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling
- (2013) B. Zhang et al. BLOOD
- Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
- (2012) D. Marin et al. BLOOD
- HIF1 is required for survival maintenance of chronic myeloid leukemia stem cells
- (2012) H. Zhang et al. BLOOD
- Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
- (2012) Bin Zhang et al. CANCER CELL
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
- (2012) B Hanfstein et al. LEUKEMIA
- Mesenchymal stem cells promote growth and angiogenesis of tumors in mice
- (2012) W-H Huang et al. ONCOGENE
- IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development
- (2011) Damien Reynaud et al. CANCER CELL
- Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia
- (2011) Thomas Schmidt et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting
- (2011) Marina Y. Konopleva et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
- (2011) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes
- (2011) A Pardanani et al. LEUKEMIA
- Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
- (2011) Anna Kreutzman et al. PLoS One
- Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia
- (2010) S. M. Kornblau et al. BLOOD
- Plasma Transforming Growth Factor α and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21
- (2010) Christina L. Addison et al. JOURNAL OF CLINICAL ONCOLOGY
- TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
- (2010) Kazuhito Naka et al. NATURE
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Differential Effects of EGFR Ligands on Endocytic Sorting of the Receptor
- (2009) Kirstine Roepstorff et al. TRAFFIC
- Clinical significance of pretreatment serum amphiregulin and transforming growth factor-α, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer
- (2008) Katsuhiro Masago et al. CANCER SCIENCE
- Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
- (2008) H F S Negaard et al. LEUKEMIA
- The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia
- (2008) Oliver Hantschel et al. Molecular Oncology
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now